Retinalamin for Retinal Health & Vision Support — Bioregulators
Khavinson bioregulator pharmaceutical for retinal tissue regeneration and vision preservation.
Overview
Retinalamin is a Khavinson natural bioregulator complex extracted from animal retinal tissue, representing one of the six approved pharmaceutical-grade bioregulator drugs. It contains a spectrum of peptides that specifically target retinal cells, supporting photoreceptor function, retinal metabolism, and visual signal processing. Retinalamin has the strongest clinical evidence among bioregulators for eye health, with extensive use in ophthalmology for age-related macular degeneration (AMD), diabetic retinopathy, retinitis pigmentosa, and post-surgical retinal recovery. Clinical studies demonstrate significant improvements in visual acuity, electroretinography parameters, and retinal thickness preservation.
Indications
- Age-related macular degeneration (AMD) - dry and wet forms
- Diabetic retinopathy and diabetic macular edema
- Retinitis pigmentosa and inherited retinal dystrophies
- Glaucomatous optic neuropathy
- Post-surgical retinal recovery
- Central serous chorioretinopathy
- Myopic retinal degeneration
- General retinal health preservation with aging
Mechanism of Action
AMD, diabetic retinopathy, retinal dystrophies, or age-related retinal cell loss affecting visual function
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Retinalamin | 5 mg | Once daily for 10 days | Standard ophthalmological protocol for retinal conditions |
| Retinalamin | 5 mg | Once daily for 10 days | Alternative route when parabulbar injection unavailable |
| Retinalamin | 20 mg | Once daily for 2-3 months | Oral maintenance for ongoing retinal support |
Evidence Grade
GRADE B
Safety & Contraindications
- Approved pharmaceutical drug in Russia/CIS with extensive clinical safety data
- Administered via parabulbar or intramuscular injection in clinical settings
- No significant adverse effects reported in clinical trials
- Mild injection site reactions possible (transient)
- Not a replacement for standard ophthalmological treatments
- Use under ophthalmologist supervision for retinal conditions
- Monitor intraocular pressure in glaucoma patients
- Safe for long-term retinal health preservation